Download PDF
Semin Neurol 2023; 43(05): 776-790
DOI: 10.1055/s-0043-1775595
Review Article

Neuroprognostication for Patients with Amyotrophic Lateral Sclerosis: An Updated, Evidence-Based Review

Christina Martin Schaff
1   Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
,
Jerome E. Kurent
2   Department of Neurology and Medicine, Medical University of South Carolina, Charleston, South Carolina
3   Department of Neurology, ALS Multidisciplinary Clinic, Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina
,
Sherry Kolodziejczak
4   ALS Clinic Treatment Center of Excellence, Crestwood Medical Center, Huntsville, Alabama
,
Michelle Milic
5   Division of Pulmonary, Critical Care, and Sleep Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia
6   Division of Palliative Care Medicine, MedStar Georgetown University Hospital, Washington, District of Columbia
,
Laura A. Foster
7   Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado
,
Ambereen K. Mehta
1   Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
8   Palliative Care Program, Division of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder that presents and progresses in various ways, making prognostication difficult. Several paradigms exist for providers to elucidate prognosis in a way that addresses not only the amount of time a patient has to live, but also a patient's quality of their life moving forward. Prognostication, with regard to both survivability and quality of life, is impacted by several features that include, but are not limited to, patient demographics, clinical features on presentation, and over time, access to therapy, and access to multidisciplinary clinics. An understanding of the impact that these features have on the life of a patient with ALS can help providers to develop a better and more personalized approach for patients related to their clinical prognosis after a diagnosis is made. The ultimate goal of prognostication is to empower patients with ALS to take control and make decisions with their care teams to ensure that their goals are addressed and met.

Keywords

ALS - prognosis - quality of life - palliative care - multidisciplinary clinic


Publication History

Article published online:
26 September 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017; 377 (02) 162-172
    CrossrefPubMedGoogle Scholar
  • 2 Mehta P, Raymond J, Punjani R. et al. Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotroph Lateral Scler Frontotemporal Degener 2023; 24 (1–2): 108-116
    CrossrefPubMedGoogle Scholar
  • 3 Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 2020; 27 (10) 1918-1929
    CrossrefPubMedGoogle Scholar
  • 4 Westeneng HJ, Debray TPA, Visser AE. et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018; 17 (05) 423-433
    CrossrefPubMedGoogle Scholar
  • 5 Miller RG, Jackson CE, Kasarskis EJ. et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73 (15) 1227-1233
    CrossrefPubMedGoogle Scholar
  • 6 Mehta P, Antao V, Kaye W. et al; Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, Centers for Disease Control and Prevention (CDC). Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR suppl 2014; 63 (07) 1-14
    PubMedGoogle Scholar
  • 7 Mehta P, Kaye W, Raymond J. et al. Prevalence of amyotrophic lateral sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep 2018; 67 (46) 1285-1289
    CrossrefPubMedGoogle Scholar
  • 8 Yamakawa M, Dwyer S, Song X, Statland J. Demographics, clinical characteristics, and prognostic factors of amyotrophic lateral sclerosis in Midwest. Muscle Nerve 2022; 65 (02) 217-224
    CrossrefPubMedGoogle Scholar
  • 9 Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol 2019; 32 (05) 771-776
    CrossrefPubMedGoogle Scholar
  • 10 Logroscino G, Piccininni M. Amyotrophic lateral sclerosis descriptive epidemiology: the origin of geographic difference. Neuroepidemiology 2019; 52 (1–2): 93-103
    CrossrefPubMedGoogle Scholar
  • 11 Mehta P, Raymond J, Punjani R. et al. Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016. Amyotroph Lateral Scler Frontotemporal Degener 2022; 23 (5-6): 378-382
    CrossrefPubMedGoogle Scholar
  • 12 Antao VC, Horton DK. The National Amyotrophic Lateral Sclerosis (ALS) Registry. J Environ Health 2012; 75 (01) 28-30
    PubMedGoogle Scholar
  • 13 Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015. Amyotroph Lateral Scler Frontotemporal Degener 2019; 20 (5–6): 413-420
    CrossrefPubMedGoogle Scholar
  • 14 Shimizu T, Nakayama Y, Matsuda C. et al. Prognostic significance of body weight variation after diagnosis in ALS: a single-centre prospective cohort study. J Neurol 2019; 266 (06) 1412-1420
    CrossrefPubMedGoogle Scholar
  • 15 Bandres-Ciga S, Noyce AJ, Hemani G. et al; ITALSGEN Consortium, International ALS Genomics Consortium. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 2019; 85 (04) 470-481
    CrossrefPubMedGoogle Scholar
  • 16 Bozzoni V, Pansarasa O, Diamanti L, Nosari G, Cereda C, Ceroni M. Amyotrophic lateral sclerosis and environmental factors. Funct Neurol 2016; 31 (01) 7-19
    PubMedGoogle Scholar
  • 17 Moglia C, Calvo A, Grassano M. et al; Piemonte and Valle d'Aosta Register for ALS (PARALS). Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry 2019; 90 (06) 666-673
    CrossrefPubMedGoogle Scholar
  • 18 De Marchi F, Sarnelli MF, Solara V, Bersano E, Cantello R, Mazzini L. Depression and risk of cognitive dysfunctions in amyotrophic lateral sclerosis. Acta Neurol Scand 2019; 139 (05) 438-445
    CrossrefPubMedGoogle Scholar
  • 19 Dorst J, Chen L, Rosenbohm A. et al. Prognostic factors in ALS: a comparison between Germany and China. J Neurol 2019; 266 (06) 1516-1525
    CrossrefPubMedGoogle Scholar
  • 20 Korner S, Kammeyer J, Zapf A. et al. Influence of environment and lifestyle on incidence and progress of amyotrophic lateral sclerosis in a German ALS population. Aging Dis 2019; 10 (02) 205-216
    CrossrefPubMedGoogle Scholar
  • 21 Dickerson AS, Hansen J, Kioumourtzoglou MA, Specht AJ, Gredal O, Weisskopf MG. Study of occupation and amyotrophic lateral sclerosis in a Danish cohort. Occup Environ Med 2018; 75 (09) 630-638
    CrossrefPubMedGoogle Scholar
  • 22 Xu L, Liu T, Liu L. et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol 2020; 267 (04) 944-953
    CrossrefPubMedGoogle Scholar
  • 23 Luna J, Diagana M, Ait Aissa L. et al; TROPALS Collaboration. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS study. J Neurol Neurosurg Psychiatry 2019; 90 (01) 20-29
    CrossrefPubMedGoogle Scholar
  • 24 Su WM, Cheng YF, Jiang Z. et al. Predictors of survival in patients with amyotrophic lateral sclerosis: a large meta-analysis. EBioMedicine 2021; 74: 103732
    CrossrefPubMedGoogle Scholar
  • 25 Kamel F, Umbach DM, Munsat TL, Shefner JM, Sandler DP. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology 1999; 18 (04) 194-202
    CrossrefPubMedGoogle Scholar
  • 26 McKay KA, Smith KA, Smertinaite L, Fang F, Ingre C, Taube F. Military service and related risk factors for amyotrophic lateral sclerosis. Acta Neurol Scand 2021; 143 (01) 39-50
    CrossrefPubMedGoogle Scholar
  • 27 Rosen DR, Siddique T, Patterson D. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362 (6415) 59-62
    CrossrefPubMedGoogle Scholar
  • 28 Chia R, Chiò A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 2018; 17 (01) 94-102
    CrossrefPubMedGoogle Scholar
  • 29 Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017; 88 (07) 540-549
    CrossrefPubMedGoogle Scholar
  • 30 Goutman SA, Hardiman O, Al-Chalabi A. et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol 2022; 21 (05) 480-493
    CrossrefPubMedGoogle Scholar
  • 31 Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu, Zn superoxide dismutase. Neurology 1997; 48 (01) 55-57
    CrossrefPubMedGoogle Scholar
  • 32 Chiò A, Moglia C, Canosa A. et al. ALS phenotype is influenced by age, sex, and genetics: a population-based study. Neurology 2020; 94 (08) e802-e810
    CrossrefPubMedGoogle Scholar
  • 33 Majounie E, Renton AE, Mok K. et al; Chromosome 9-ALS/FTD Consortium, French research network on FTLD/FTLD/ALS, ITALSGEN Consortium. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11 (04) 323-330
    CrossrefPubMedGoogle Scholar
  • 34 Breevoort S, Gibson S, Figueroa K, Bromberg M, Pulst S. Expanding clinical spectrum of C9ORF72-related disorders and promising therapeutic strategies: a review. Neurol Genet 2022; 8 (03) e670
    CrossrefPubMedGoogle Scholar
  • 35 Miller T, Cudkowicz M, Shaw PJ. et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 2020; 383 (02) 109-119
    CrossrefPubMedGoogle Scholar
  • 36 Thouvenot E, Demattei C, Lehmann S. et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol 2020; 27 (02) 251-257
    CrossrefPubMedGoogle Scholar
  • 37 Falzone YM, Domi T, Mandelli A. et al. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol 2022; 29 (07) 1930-1939
    CrossrefPubMedGoogle Scholar
  • 38 Weydt P, Oeckl P, Huss A. et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016; 79 (01) 152-158
    CrossrefPubMedGoogle Scholar
  • 39 Huang F, Zhu Y, Hsiao-Nakamoto J. et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2020; 7 (07) 1103-1116
    CrossrefPubMedGoogle Scholar
  • 40 Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009; 4: 3
    CrossrefPubMedGoogle Scholar
  • 41 Shoesmith CL, Findlater K, Rowe A, Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 2007; 78 (06) 629-631
    CrossrefPubMedGoogle Scholar
  • 42 Gautier G, Verschueren A, Monnier A, Attarian S, Salort-Campana E, Pouget J. ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis. Amyotroph Lateral Scler 2010; 11 (04) 379-382
    CrossrefPubMedGoogle Scholar
  • 43 Shellikeri S, Karthikeyan V, Martino R. et al. The neuropathological signature of bulbar-onset ALS: a systematic review. Neurosci Biobehav Rev 2017; 75: 378-392
    CrossrefPubMedGoogle Scholar
  • 44 Crockford C, Newton J, Lonergan K. et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology 2018; 91 (15) e1370-e1380
    CrossrefPubMedGoogle Scholar
  • 45 Xu Z, Alruwaili ARS, Henderson RD, McCombe PA. Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. J Neurol Sci 2017; 376: 16-23
    CrossrefPubMedGoogle Scholar
  • 46 Kaufmann P, Levy G, Thompson JLP. et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology 2005; 64 (01) 38-43
    CrossrefPubMedGoogle Scholar
  • 47 Fournier CN, Bedlack R, Quinn C. et al. Development and validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA Neurol 2020; 77 (04) 480-488
    CrossrefPubMedGoogle Scholar
  • 48 Javad Mousavi SA, Zamani B, Shahabi Shahmiri S. et al. Pulmonary function tests in patients with amyotrophic lateral sclerosis and the association between these tests and survival. Iran J Neurol 2014; 13 (03) 131-137
    PubMedGoogle Scholar
  • 49 Zhang QJ, Huang JC, Chen J, Hu W, Xu LQ, Guo QF. Peak expiratory flow is a reliably household pulmonary function parameter correlates with disease severity and survival of patients with amyotrophic lateral sclerosis. BMC Neurol 2022; 22 (01) 105
    CrossrefPubMedGoogle Scholar
  • 50 Al Khleifat A, Balendra R, Fang T, Al-Chalabi A. Intuitive staging correlates with King's clinical stage. Amyotroph Lateral Scler Frontotemporal Degener 2021; 22 (5-6): 336-340
    CrossrefPubMedGoogle Scholar
  • 51 Balendra R, Jones A, Jivraj N. et al; UK-MND LiCALS Study Group, Mito Target ALS Study Group. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry 2015; 86 (01) 45-49
    CrossrefPubMedGoogle Scholar
  • 52 Corcia P, Beltran S, Lautrette G, Bakkouche S, Couratier P. Staging amyotrophic lateral sclerosis: a new focus on progression. Rev Neurol (Paris) 2019; 175 (05) 277-282
    CrossrefPubMedGoogle Scholar
  • 53 Fang T, Al Khleifat A, Stahl DR. et al; Uk-Mnd LicalS. Comparison of the King's and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18 (3–4): 227-232
    CrossrefPubMedGoogle Scholar
  • 54 de Jongh AD, Braun N, Weber M. et al. Characterising ALS disease progression according to El Escorial and Gold Coast criteria. J Neurol Neurosurg Psychiatry 2022; 93 (08) 865-870
    CrossrefPubMedGoogle Scholar
  • 55 Shefner JM, Al-Chalabi A, Baker MR. et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 2020; 131 (08) 1975-1978
    CrossrefPubMedGoogle Scholar
  • 56 Salameh JS, Brown Jr RH, Berry JD. Amyotrophic lateral sclerosis: review. Semin Neurol 2015; 35 (04) 469-476
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol 2006; 253 (11) 1428-1436
    CrossrefPubMedGoogle Scholar
  • 58 del Aguila MA, Longstreth Jr WT, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology 2003; 60 (05) 813-819
    CrossrefPubMedGoogle Scholar
  • 59 Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ. The Netherlands ALS Consortium. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. J Neurol Sci 1997; 152 (Suppl. 01) S10-S17
    CrossrefPubMedGoogle Scholar
  • 60 Bensimon G, Lacomblez L, Meininger V. ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330 (09) 585-591
    CrossrefPubMedGoogle Scholar
  • 61 Lacomblez L, Bensimon G, Leigh PN. et al; ALS/Riluzole Study Group-II. A confirmatory dose-ranging study of riluzole in ALS. Neurology 1996; 47 (6, suppl 4): S242-S250
    CrossrefPubMedGoogle Scholar
  • 62 Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler 2006; 7 (04) 241-245
    CrossrefPubMedGoogle Scholar
  • 63 Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16 (07) 505-512
    CrossrefPubMedGoogle Scholar
  • 64 Paganoni S, Watkins C, Cawson M. et al. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. Muscle Nerve 2022; 66 (02) 136-141
    CrossrefPubMedGoogle Scholar
  • 65 Paganoni S, Macklin EA, Hendrix S. et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 2020; 383 (10) 919-930
    CrossrefPubMedGoogle Scholar
  • 66 Miller TM, Cudkowicz ME, Genge A. et al; VALOR and OLE Working Group. Trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med 2022; 387 (12) 1099-1110
    CrossrefPubMedGoogle Scholar
  • 67 Sever B, Ciftci H, DeMirci H. et al. Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis. Int J Mol Sci 2022; 23 (05) 2400
    CrossrefPubMedGoogle Scholar
  • 68 Tornese P, Lalli S, Cocco A, Albanese A. Review of disease-modifying drug trials in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2022; 93 (05) 521-529
    CrossrefPubMedGoogle Scholar
  • 69 Fang T, Je G, Pacut P, Keyhanian K, Gao J, Ghasemi M. Gene therapy in amyotrophic lateral sclerosis. Cells 2022; 11 (13) 2066
    CrossrefPubMedGoogle Scholar
  • 70 Ito D. Promise of nucleic acid therapeutics for amyotrophic lateral sclerosis. Ann Neurol 2022; 91 (01) 13-20
    CrossrefPubMedGoogle Scholar
  • 71 Mueller C, Berry JD, McKenna-Yasek DM. et al. SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS. N Engl J Med 2020; 383 (02) 151-158
    CrossrefPubMedGoogle Scholar
  • 72 Morgan RK, McNally S, Alexander M, Conroy R, Hardiman O, Costello RW. Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2005; 171 (03) 269-274
    CrossrefPubMedGoogle Scholar
  • 73 Polkey MI, Lyall RA, Yang K, Johnson E, Leigh PN, Moxham J. Respiratory muscle strength as a predictive biomarker for survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2017; 195 (01) 86-95
    CrossrefPubMedGoogle Scholar
  • 74 Walsh LJ, Deasy KF, Gomez F. et al. Use of non-invasive ventilation in motor neuron disease - a retrospective cohort analysis. Chron Respir Dis 2021 ;18:14799731211063886
    PubMedGoogle Scholar
  • 75 Andersen PM, Abrahams S, Borasio GD. et al; EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. Eur J Neurol 2012; 19 (03) 360-375
    CrossrefPubMedGoogle Scholar
  • 76 Vitacca M, Montini A, Lunetta C. et al; ALS RESPILOM Study Group. Impact of an early respiratory care programme with non-invasive ventilation adaptation in patients with amyotrophic lateral sclerosis. Eur J Neurol 2018; 25 (03) 556-e33
    CrossrefPubMedGoogle Scholar
  • 77 Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006; 5 (02) 140-147
    CrossrefPubMedGoogle Scholar
  • 78 Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124 (Pt 10): 2000-2013
    CrossrefPubMedGoogle Scholar
  • 79 Piepers S, van den Berg JP, Kalmijn S. et al. Effect of non-invasive ventilation on survival, quality of life, respiratory function and cognition: a review of the literature. Amyotroph Lateral Scler 2006; 7 (04) 195-200
    CrossrefPubMedGoogle Scholar
  • 80 Bach JR. Amyotrophic lateral sclerosis: predictors for prolongation of life by noninvasive respiratory aids. Arch Phys Med Rehabil 1995; 76 (09) 828-832
    CrossrefPubMedGoogle Scholar
  • 81 Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luís ML. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 1995; 129 (suppl): 19-26
    CrossrefPubMedGoogle Scholar
  • 82 NICE Clinical Guidelines No 105. Motor Neurone Disease: The Use of Non-Invasive Ventilation in the Management of Motor Neurone Disease. London: National Institute for Health and Clinical Excellence (NICE); 2010
    Google Scholar
  • 83 Cazzolli PA, Brooks BR, Nakayama Y. et al. The oral secretion scale and prognostic factors for survival in subjects with amyotrophic lateral sclerosis. Respir Care 2020; 65 (08) 1063-1076
    CrossrefPubMedGoogle Scholar
  • 84 Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ. Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology 2003; 61 (02) 171-177
    CrossrefPubMedGoogle Scholar
  • 85 Benditt JO. Respiratory complications of amyotrophic lateral sclerosis. Semin Respir Crit Care Med 2002; 23 (03) 239-247
    Article in Thieme ConnectPubMedGoogle Scholar
  • 86 Cleary S, Misiaszek JE, Kalra S, Wheeler S, Johnston W. The effects of lung volume recruitment on coughing and pulmonary function in patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14 (02) 111-115
    CrossrefPubMedGoogle Scholar
  • 87 McDermott C, Shaw P, Cooper C. et al; DiPALS Writing Committee, DiPALS Study Group Collaborators. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol 2015; 14 (09) 883-892
    CrossrefPubMedGoogle Scholar
  • 88 Niedermeyer S, Murn M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest 2019; 155 (02) 401-408
    CrossrefPubMedGoogle Scholar
  • 89 Takei K, Tsuda K, Takahashi F, Hirai M, Palumbo J. An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18 (sup1): 88-97
    CrossrefPubMedGoogle Scholar
  • 90 Hayashi N, Atsuta N, Yokoi D. et al. Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan. J Neurol Neurosurg Psychiatry 2020; 91 (03) 285-290
    CrossrefPubMedGoogle Scholar
  • 91 Spittel S, Maier A, Kettemann D. et al. Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: utilization and survival rates in a cohort study over 12 years in Germany. Eur J Neurol 2021; 28 (04) 1160-1171
    CrossrefPubMedGoogle Scholar
  • 92 Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999; 53 (05) 1059-1063
    CrossrefPubMedGoogle Scholar
  • 93 Beghi E, Millul A, Logroscino G, Vitelli E, Micheli A. SLALOM GROUP. Outcome measures and prognostic indicators in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008; 9 (03) 163-167
    CrossrefPubMedGoogle Scholar
  • 94 Limousin N, Blasco H, Corcia P. et al. Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. J Neurol Sci 2010; 297 (1–2): 36-39
    CrossrefPubMedGoogle Scholar
  • 95 Burkhardt C, Neuwirth C, Sommacal A, Andersen PM, Weber M. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PLoS One 2017; 12 (05) e0177555
    CrossrefPubMedGoogle Scholar
  • 96 Bond L, Ganguly P, Khamankar N. et al. A comprehensive examination of percutaneous endoscopic gastrostomy and its association with amyotrophic lateral sclerosis patient outcomes. Brain Sci 2019; 9 (09) 223
    CrossrefPubMedGoogle Scholar
  • 97 Spataro R, Ficano L, Piccoli F, La Bella V. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. J Neurol Sci 2011; 304 (1–2): 44-48
    CrossrefPubMedGoogle Scholar
  • 98 McDonnell E, Schoenfeld D, Paganoni S, Atassi N. Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. Neurology 2017; 89 (14) 1483-1489
    CrossrefPubMedGoogle Scholar
  • 99 Katzberg HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2011; 2011 (01) CD004030
    PubMedGoogle Scholar
  • 100 Hesters A, Amador MDM, Debs R. et al. Predictive factors for prognosis after gastrostomy placement in routine non-invasive ventilation users ALS patients. Sci Rep 2020; 10 (01) 15117
    CrossrefPubMedGoogle Scholar
  • 101 World Health Organization. Palliative Care. Published August 5, 2020. Accessed April 6, 2023 at: https://www.who.int/news-room/fact-sheets/detail/palliative-care
    PubMedGoogle Scholar
  • 102 National Institute for Health and Care Excellence (NICE). Motor Neurone Disease: Assessment and Management. London: National Institute for Health and Clinical Excellence (NICE); 2019
    Google Scholar
  • 103 Bede P, Oliver D, Stodart J. et al. Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. J Neurol Neurosurg Psychiatry 2011; 82 (04) 413-418
    CrossrefPubMedGoogle Scholar
  • 104 Oliver DJ. Palliative care in motor neurone disease: where are we now?. Palliat Care 2019; 12: 1178224218813914
    PubMedGoogle Scholar
  • 105 Kurent JE, Oliver D, Blank RH. Introduction to public policy of ALS/MND. In: Blank RH, Kurent JE, Oliver D. eds. Public Policy in ALS/MND Care: An International Perspective. London: Palgrave Macmillan; 2021
    CrossrefGoogle Scholar
  • 106 Mehta AK, Jackson NJ, Wiedau-Pazos M. Palliative care consults in an inpatient setting for patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2021; 38 (09) 1091-1098
    CrossrefPubMedGoogle Scholar
  • 107 Hafer J, Jensen S, Wiedau-Pazos M, Mehta AK. Assessment of feasibility and utility of universal referral to specialty palliative care in a multidisciplinary amyotrophic lateral sclerosis clinic: a cohort study. Muscle Nerve 2021; 63 (06) 818-823
    CrossrefPubMedGoogle Scholar
  • 108 Fahrner-Scott K, Zapata C, O'Riordan DL. et al. Embedded palliative care for amyotrophic lateral sclerosis: a pilot program and lessons learned. Neurol Clin Pract 2022; 12 (01) 68-75
    CrossrefPubMedGoogle Scholar
  • 109 Klock Z, Dobak S, Houseman G, Cunningham AT, Kreher M. Advance care planning and healthcare utilization in patients with amyotrophic lateral sclerosis: a retrospective chart review. Am J Hosp Palliat Care 2022; 39 (10) 1152-1156
    CrossrefPubMedGoogle Scholar
  • 110 Sukockien E, Iancu Ferfoglia R, Boegli M. et al. Early advance care planning in amyotrophic lateral sclerosis patients: results of a systematic intervention by a palliative care team in a multidisciplinary management programme – a 4-year cohort study. Swiss Med Wkly 2021; 151: w20484
    CrossrefPubMedGoogle Scholar
  • 111 Burchardi N, Rauprich O, Hecht M, Beck M, Vollmann J. Discussing living wills. A qualitative study of a German sample of neurologists and ALS patients. J Neurol Sci 2005; 237 (1-2): 67-74
    CrossrefPubMedGoogle Scholar
  • 112 Sean Morrison R. Advance directives/care planning: clear, simple, and wrong. J Palliat Med 2020; 23 (07) 878-879
    CrossrefPubMedGoogle Scholar
  • 113 Morrison RS, Meier DE, Arnold RM. What's wrong with advance care planning?. JAMA 2021; 326 (16) 1575-1576
    CrossrefPubMedGoogle Scholar
  • 114 Cipolletta S, Reggiani M. End-of-life care after the legal introduction of advance directives: a qualitative study involving healthcare professionals and family caregivers of patients with amyotrophic lateral sclerosis. Palliat Med 2021; 35 (01) 209-218
    CrossrefPubMedGoogle Scholar
  • 115 The ALS Association. More information on certified centers & clinics. Accessed November 14, 2022 at: https://www.als.org/local-support/certified-centers-clinics/more-information-certified-centers-clinics
    PubMedGoogle Scholar
  • 116 Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry 2003; 74 (09) 1258-1261
    CrossrefPubMedGoogle Scholar
  • 117 Paipa AJ, Povedano M, Barcelo A. et al. Survival benefit of multidisciplinary care in amyotrophic lateral sclerosis in Spain: association with noninvasive mechanical ventilation. J Multidiscip Healthc 2019; 12: 465-470
    CrossrefPubMedGoogle Scholar
  • 118 Aridegbe T, Kandler R, Walters SJ, Walsh T, Shaw PJ, McDermott CJ. The natural history of motor neuron disease: assessing the impact of specialist care. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14 (01) 13-19
    CrossrefPubMedGoogle Scholar
  • 119 Rooney J, Byrne S, Heverin M. et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry 2015; 86 (05) 496-501
    CrossrefPubMedGoogle Scholar